Targeted Degradation of Phosphorylated p38 MAPK (Tyr182) as a Novel Therapeutic Strategy for Alzheimer’s Disease

Literature Analysis & Product Highlight

Literature Information

This review summarizes cutting‑edge research on selective degradation of phosphorylated p38 MAPK (Tyr182) as a transformative approach to treat Alzheimer’s disease (AD). The work highlights how PROTAC‑mediated targeted protein degradation reverses core AD pathologies, including neuroinflammation, amyloid‑beta plaque formation, and cognitive decline.

Research Background

Alzheimer’s disease is defined by three pathological hallmarks: amyloid‑beta (Aβ) plaque deposition, neurofibrillary tangles, and chronic neuroinflammation. The stress‑activated kinase p38 MAPK is strongly implicated in disease progression. When phosphorylated at Tyr182, activated p‑p38 drives inflammatory signaling, synaptic dysfunction, and neuronal damage. Traditional kinase inhibitors suffer from poor selectivity, off‑target effects, and incomplete suppression of pathological signaling. In contrast, PROTAC technology enables highly specific degradation of pathogenic p‑p38 while preserving physiological p38 function, offering a safer and more effective therapeutic paradigm.

Research Approach

The study employed conformation‑selective ligand design to target the unique structural interface exposed upon p38 MAPK phosphorylation at Tyr182. These ligands were conjugated to E3 ubiquitin ligase ligands to generate selective PROTAC molecules. These compounds specifically recruit the ubiquitin‑proteasome system to degrade activated p‑p38 without affecting total p38 levels. In vivo efficacy was evaluated in AD mouse models using intranasal delivery to cross the blood–brain barrier, followed by assessment of neuroinflammation, Aβ burden, synaptic function, and cognitive behavior.

Key Research Outcomes

• Selective PROTACs eliminate phosphorylated p38 MAPK (Tyr182) in the brain without altering endogenous p38.
• Reduced microgliosis, astrogliosis, and pro‑inflammatory cytokine release.
• Diminished Aβ plaque formation and tau hyperphosphorylation.
• Improved synaptic plasticity and significant recovery of learning and memory.
• Demonstrated that conformation‑specific degradation is a viable strategy for neurodegenerative disease intervention.

Product Empowerment by ANT BIO PTE. LTD.

ANT BIO’s Phospho‑p38 MAPK (Tyr182) Recombinant Rabbit Monoclonal Antibody (Cat. S0B0897) is an essential tool for validating this therapeutic mechanism. It enables highly specific detection of activated p38 in Western blot, immunofluorescence, and flow cytometry applications, supporting target validation, pharmacodynamic studies, and translational research. Its exceptional specificity for the Tyr182 phosphorylation site ensures reliable quantification of PROTAC‑mediated degradation.

Brand Mission

ANT BIO PTE. LTD. is committed to providing researchers with high‑quality antibodies, proteins, kits, and universal life science reagents. Through our sub‑brands Absin, Starter, and UA, we deliver innovative reagents for neuroscience, immunology, oncology, and molecular medicine.

Related Product List

• Phospho‑p38 MAPK (Tyr182) Recombinant Rabbit mAb (S0B0897)
• p38 MAPK pathway‑related ELISA kits
• Neuroinflammation research antibody panel

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high‑quality, reliable reagents and comprehensive solutions. Our specialized sub‑brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer‑centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.